Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-08, Stock:LLY, The news for the past five days is as follows:
2019-02-01: NEWS1: Cramer&apos;s game plan: Be ready to &apos;buy the next dip&apos; in this &apos;ideal backdrop for stocks&apos;.NEWS2: Cramer's game plan: Be ready to 'buy the next dip' in this 'ideal backdrop for stocks'.NEWS3: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.NEWS4: Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat.NEWS5: Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat.NEWS6: Notable ETF Inflow Detected - XLV, AMGN, ABBV, LLY.NEWS7: Notable ETF Inflow Detected - XLV, AMGN, ABBV, LLY.NEWS8: Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat.NEWS9: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS10: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS11: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS12: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS13: Pharma Catches Another Case Of M&A Fever.NEWS14: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS15: The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant.NEWS16: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS17: Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction.NEWS18: Eli Lilly, Loxo Oncology Report Expiration Of HSR Act Waiting Period.NEWS19: Eli Lilly, Loxo Oncology Report Expiration Of HSR Act Waiting Period.NEWS20: J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study.NEWS21: J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study.NEWS22: J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study.
2019-02-04: NEWS1: Eli Lilly Is Trading Strong Ahead of Earnings on Wednesday.NEWS2: Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy.NEWS3: Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy.NEWS4: 5 of the Best Biotech Stocks to Buy Now.NEWS5: Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy.NEWS6: Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis.NEWS7: Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2.NEWS8: Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2.
2019-02-05: NEWS1: Pre-Market Earnings Report for February 6, 2019 :  LLY, GM, BSX, REGN, HUM, CTSH, CMI, GSK, FDC, TTWO, BIP, JEC.NEWS2: Pre-Market Earnings Report for February 6, 2019 :  LLY, GM, BSX, REGN, HUM, CTSH, CMI, GSK, FDC, TTWO, BIP, JEC.NEWS3: Sanofi's Myeloma Candidate Meets Goal in Phase III Study.NEWS4: Sanofi's Myeloma Candidate Meets Goal in Phase III Study.NEWS5: Roche Submits sBLA to FDA for Label Expansion of Kadcyla.NEWS6: Roche Submits sBLA to FDA for Label Expansion of Kadcyla.NEWS7: Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer.NEWS8: Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer.NEWS9: Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies.NEWS10: Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies.NEWS11: Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines.NEWS12: Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines.NEWS13: Sanofi's Myeloma Candidate Meets Goal in Phase III Study.NEWS14: Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer.NEWS15: Roche Submits sBLA to FDA for Label Expansion of Kadcyla.NEWS16: Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines.NEWS17: Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies.NEWS18: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results.
2019-02-06: NEWS1: Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript.NEWS2: Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript.NEWS3: Stocks End Lower as Wall Street Gets No Boost From State of the Union.NEWS4: Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal.NEWS5: This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag.NEWS6: Stocks end lower amid mixed corporate earnings.NEWS7: Stocks Trade Lower as Wall Street Gets No Boost From State of the Union.NEWS8: Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript.NEWS9: This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag.NEWS10: Eli Lilly Stock Falls Because 2019 Isn’t 2018.NEWS11: Stocks Mostly Lower as Wall Street Gets No Boost From State of the Union.NEWS12: Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down.NEWS13: Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down.NEWS14: Eli Lilly backs U.S. proposal on drug rebates to lower costs.NEWS15: Eli Lilly cuts 2019 forecast on trial failure, Loxo deal.NEWS16: Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View.NEWS17: Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View.NEWS18: Dow Falls as Wall Street Gets No Boost From State of the Union.NEWS19: Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down.NEWS20: Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View.NEWS21: The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering.NEWS22: Small-Caps Are Making Big Moves in This Technically Extended Market.NEWS23: Stocks making the biggest moves premarket: Eli Lilly, Humana, Disney, Spotify & more.NEWS24: [$$] Eli Lilly cuts 2019 outlook after trial failure and Loxo deal.NEWS25: Lilly lowers 2019 forecast due to drug failure, pending deal.NEWS26: Lilly lowers 2019 forecast due to drug failure, pending deal.NEWS27: Earnings Reaction History: Eli Lilly & Co., 54.5% Follow-Through Indicator, 2.5% Sensitive.NEWS28: Earnings Reaction History: Eli Lilly & Co., 54.5% Follow-Through Indicator, 2.5% Sensitive.NEWS29: [$$] Eli Lilly Swings to Profit in Latest Quarter.NEWS30: Eli Lilly Earnings Miss, Forecast Light; Stock Flirts With Buy Point.NEWS31: Eli Lilly Earnings Miss, EPS Guidance Light; Stock Threatens To Undercut Buy Point.NEWS32: Eli Lilly&apos;s stock falls after profit miss, lowered outoook.NEWS33: Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology.NEWS34: Stocks - Snap Soars in Premarket, Electronic Arts, Take-Two, Spotify Plunge.NEWS35: Eli Lilly Lowers FY19 Outlook - Quick Facts.NEWS36: Eli Lilly Lowers FY19 Outlook - Quick Facts.NEWS37: Stocks - U.S. Futures Inch Down Ahead of GM Earnings.NEWS38: Eli Lilly Earnings miss, Revenue beats In Q4.NEWS39: Eli Lilly And Co. Q4 18 Earnings Conference Call At 9:00 AM ET.NEWS40: Eli Lilly And Co. Q4 18 Earnings Conference Call At 9:00 AM ET.NEWS41: Top 5 Things to Know in The Market on Wednesday.
2019-02-07: NEWS1: Edited Transcript of LLY earnings conference call or presentation 6-Feb-19 2:00pm GMT.NEWS2: Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth.NEWS3: Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth.NEWS4: Stock Market News For Feb 7, 2019.NEWS5: Stock Market News For Feb 7, 2019.NEWS6: Stock Market News For Feb 7, 2019.NEWS7: 5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure.NEWS8: 5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure.NEWS9: Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth.NEWS10: 5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo&apos;s Failure.

Answer: Rise